TARDBP and amyotrophic lateral sclerosis: Thus, pinpointing human molecular chaperones that antagonize aberrant TDP-43 phase transitions in the cytoplasm and the nucleus could provide avenues for therapeutic intervention to halt progression of ALS/FTD5, 22, 23.